Looking for CMOs to manufacture small batches of sterile Eye drops [ENA02638]
A US-based company dedicated to developing and bringing to the commercial marketplace products that will aid vision and prevent blindness is looking for manufacturers of small batches of sterile eye drops. They are particularly interested in manufacturers who work with natural products.
14 Nov 2018

Be the first to reply

Reply

Looking for suppliers/CMOs for Intermediates (CAS: 34160-40-2 & CAS: 536-46-9) [ENA02626]
A German company specialized in providing pharmaceutical services is looking for suppliers of following intermediates:
1. CAS #34160-40-2 [6-Bromo-2-pyridinecarboxaldehyde] 250kg.
2. CAS #536-46-9 [N,N-Dimethyl-1,4-phenylenediamine Dihydrochloride] 100-500kg.
13 Nov 2018

View (1)

Reply

Looking for manufacturers to produce 4-Aminobenzoic acid from Benzocaine [ENA02612]
A mid-sized pharmaceutical company that provides a wealth of expertise while connecting companies, people and knowledge is looking for CMOs to produce 4-Aminobenzoic acid from Benzocaine via saponification while preserving API quality.
13 Nov 2018

View (1)

Reply

Looking for US based CMOs to develop and manufacture a generic lyophilized product [ENA02561]
A US-based consulting firm is looking for CMOs to develop and manufacture a generic lyophilized product. They would prefer a CMO which can help them in development, manufacturing of about 50,000 vials, labelling & packaging and NDA filing.
06 Nov 2018

View (2)

Reply

Looking for CMO to manufacture Soft Gel Capsules for dietary products [ENA02528]
A leading Nutritional Supplements distributor in Taiwan is searching for German CMOs to manufacture Soft Gel Capsules providing service from ingredient sourcing to product development. The manufacturers must have official permission/registration for manufacturing of dietary products. The forecast volume will be about 0.5 to 1 million capsules per year.
02 Nov 2018

View (1)

Reply

Looking for US based Packaging CMOs for late phase clinical supplies (oral solid dosage forms) [ENA02506]
A Korean Stock Exchange listed company is looking for US-based Packaging CMOs for late phase clinical supplies (oral solid dosage forms) with serialization support. The CMO must have a positive USFDA inspection history.
31 Oct 2018

Be the first to reply

Reply

Looking for CMOs to manufacture food-supplement capsules [ENA02437]
One of the biggest cosmetics producers in the Baltic region is looking for CMOs to manufacture food-supplement capsules for skin, hair and nails care with their private label. They would like to receive an indicative price for 100 000, 300 000 and 500 000 capsules (in bulk and in individual packages).
25 Oct 2018

View (2)

Reply

Looking for CROs to conduct Bioequivalence studies [ENA02427]
A science and innovation-driven Research and Development Company providing dosage form development and analytical services to the global pharmaceutical industry is looking for CROs to conduct Bioequivalence studies on their product.
24 Oct 2018

View (2)

Reply

Looking for CROs for Bioequivalence Studies for drug products [ENA02388]
A leading pharmaceutical company in Pakistan is looking for CROs to perform Bioequivalence studies on the dome of their drug products. The facility must have international accreditations such as FDA/EMA/GCP/GLP/WHO.
23 Oct 2018

View (1)

Reply

Looking for Insulin CMOs in the US, European, Asian and Indian market [ENA02350]
A pharmaceutical company based in Switzerland devoted to identifying, developing and marketing innovative products in reproductive and maternal health, urology, gastroenterology, endocrinology and orthopaedics is looking for suppliers of Insulin CMOs in the US, European, Asian and Indian market.
19 Oct 2018

View (1)

Reply

PharmaCompass

PharmaCompass – Grow Your Pharma Business Digitally. What is Telmisartan? Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.

ABOUT
THE PAGE

COLLAPSE